Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report released on Friday. The firm set a “hold” rating on the stock.

ONCT has been the topic of a number of other research reports. Northland Securities reiterated a “market perform” rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Brookline Capital Management reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Finally, Northland Capmk cut Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Oncternal Therapeutics presently has an average rating of “Hold” and an average target price of $10.00.

Oncternal Therapeutics Price Performance

Shares of NASDAQ ONCT opened at $0.53 on Friday. Oncternal Therapeutics has a 52 week low of $0.53 and a 52 week high of $13.14. The business’s 50 day moving average price is $1.14 and its 200 day moving average price is $4.11. The firm has a market cap of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18.

Hedge Funds Weigh In On Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics as of its most recent SEC filing. 16.05% of the stock is owned by hedge funds and other institutional investors.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.